Overview

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2026-08-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Stemline Therapeutics, Inc.

Treatments:

Everolimus
Palbociclib